Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported its provisional Q4 2023 consolidated financial results with revenue of KRW 1.07T and operating profit of KRW 350.0B, achieving an annual cumulative revenue of KRW 3.69T (+23.10% YoY) for 2023. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Samsung Biologics (207940) – Provisional Performance (Consolidated Financial Results) / 2024-01-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported its FY2023 consolidated financial results, recording revenue of KRW 3.69T (+23.1% YoY) and operating profit of KRW 1.11T (+13.2% YoY). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final Audit Figures and Subsequent Audit Report…

Read More “[Disclosure] Samsung Biologics (207940) – Change in Profit and Loss Structure Exceeding 30% (15% for Large Corporations) / 2024-01-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued its consolidated revenue guidance of KRW 4.16T for FY2024, which represents the midpoint of its projected YoY growth range (+10% to +15%). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Actual Revenue Achievement and Potential…

Read More “[Disclosure] Samsung Biologics (207940) – Outlook on Business Performance (Consolidated Financial Results) / 2024-01-24” »